HYFT
ImmunoPrecise Antibodies Ltd.
1.30$
-4.0%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +2,893.2% | +184.6% | +525.5% | +15.3% | -3.8% | +145.6% | +39.6% | -16.8% | -22.9% | -25.9% | -52.0% | |
| – | +2,721.8% | +169.7% | +45.6% | +106.5% | -22.1% | +534.6% | -23.3% | -55.2% | -31.6% | +63.3% | -13.7% | |
| – | +8,749.5% | +656.4% | -30.0% | +202.9% | -52.4% | +1,502.6% | -28.2% | -72.4% | -58.2% | +208.3% | +6.2% | |
| – | +1,284.0% | +364.6% | -30.0% | +202.9% | -52.4% | +1,502.6% | -28.2% | -72.4% | -58.2% | +208.3% | +6.2% | |
| – | +22,445.4% | +4.1% | +373.1% | -12.1% | +87.5% | -0.9% | -6.0% | +13.8% | +4.8% | +18.2% | -25.6% | |
| – | – | +1,999.7% | +605.5% | +413.9% | -61.4% | +47.1% | +34.1% | +27.6% | +3.8% | -2.1% | -76.6% | |
| – | – | – | – | +68.7% | -4.2% | -1.7% | +153.3% | -2.7% | -59.9% | +7.1% | -100.0% | |
| – | – | – | – | +108.2% | -1.6% | -26.9% | +434.7% | -4.5% | -23.8% | -95.5% | – | |
| – | +85.4% | +77.3% | +1,318.6% | -13.4% | +18.5% | -17.6% | +83.0% | +9.0% | +30.3% | -20.1% | -53.8% | |
| – | +51.4% | +117.1% | +411.9% | +68.2% | +10.1% | -23.4% | +53.0% | -36.3% | +37.2% | +10.9% | -35.9% | |
| – | – | – | – | +1,347.6% | +1.7% | -37.8% | +28.6% | -15.7% | -19.4% | +18.4% | -75.3% | |
| – | -44.2% | +559.1% | +205.6% | -21.5% | -15.1% | -0.7% | +254.5% | -47.9% | +76.0% | +20.8% | -21.0% | |
| – | – | +240.4% | +310.8% | +42.2% | -16.5% | +277.3% | +32.3% | -23.2% | -41.3% | -30.3% | -50.4% | |
| – | – | -602.9% | – | – | – | – | – | – | – | – | – | |
| – | +263.4% | +98.2% | +129.9% | +37.7% | +8.7% | +20.9% | +19.5% | +26.5% | +3.0% | +30.2% | +38.9% |
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.